Dayvigo Overdose and Accidental Excess Dose: What to Do and What to Expect

What Happens Biologically After a Lemborexant Overdose

Lemborexant blocks both orexin-1 (OX1R) and orexin-2 (OX2R) receptors in the lateral hypothalamus. Orexin peptides (also called hypocretins) normally promote and sustain wakefulness; antagonizing both receptor subtypes simultaneously shifts the brain toward sleep-like states 1. In overdose, this suppression becomes exaggerated and prolonged.

The Orexin System and Why Dose Matters

Orexin neurons project widely to the locus coeruleus, dorsal raphe, and tuberomammillary nucleus, all of which drive arousal 2. Blocking both receptor subtypes at supratherapeutic concentrations removes that wake-promoting drive across every downstream nucleus simultaneously. The result is a sedation depth and duration that scales with plasma concentration, not a binary on/off effect 3.

The FDA-approved ceiling dose is 10 mg per night. The SUNRISE-2 trial (N=949, 12-month duration) found no incremental efficacy signal beyond 10 mg while adverse-effect rates climbed, supporting the labeling limit 4. Taking two or three tablets at once pushes plasma levels into a range that has not been studied for safety and extends the effective half-life well beyond the labeled 17 to 19 hours 5.

Pharmacokinetic Factors That Worsen Overdose Severity

• Hepatic impairment. Lemborexant is metabolized primarily by CYP3A4. Moderate hepatic impairment roughly doubles AUC; the FDA label restricts use to 5 mg maximum in that population 5.
• CYP3A inhibitors. Co-administration with strong inhibitors such as ketoconazole or clarithromycin can increase lemborexant exposure by 4-fold or more, converting a single therapeutic dose into a functional overdose 6.
• Age. Older adults (65+) clear lemborexant more slowly. SUNRISE-2 data showed somnolence rates approximately 1.5 times higher in patients over 65 than in younger adults 4.
• Alcohol. Ethanol potentiates CNS depression through separate mechanisms. A single standard drink combined with an excess lemborexant dose may produce additive sedation disproportionate to either agent alone 7.

Symptoms and Clinical Timeline After an Excess Dose

Signs of lemborexant toxicity follow a predictable sequence tied to plasma concentration peaks. Tmax under fasting conditions is approximately 1 to 3 hours after ingestion 5.

Early Phase (0 to 3 Hours)

• Excessive somnolence and difficulty staying awake
• Slurred speech, ataxia
• Impaired coordination (falls risk is significant)
• Cataplexy-like muscle weakness in rare cases, reflecting OX2R's role in muscle tone regulation 8

Mid Phase (3 to 12 Hours)

• Deepening sedation progressing toward stupor at very high doses
• Reduced respiratory rate in the setting of polypharmacy or opioid co-ingestion
• Hypotension (mild; orthostatic)
• Miosis reported anecdotally but not confirmed in controlled overdose data

Late Phase (12 to 36 Hours)

The long half-life of 17 to 19 hours means symptoms may persist well into the following day. Patients who appear "better" at 6 hours may worsen again as entero-hepatic circulation redistributes drug. The FDA prescribing information specifically warns that next-day impairment occurs even at the 10 mg therapeutic dose in some individuals 5; with an overdose, this window extends proportionally.

A systematic review of orexin receptor antagonist toxicology (Kishi et al., CNS Drugs 2020) found that the most consistent finding across DORA overdose cases was prolonged somnolence lasting more than 24 hours, with full neurological recovery in all documented cases that did not involve coingestants 9.

Immediate Actions: Step-by-Step Response

Step 1. Establish safety. If the person is unconscious or not breathing, call 911 before anything else. Do not leave them alone.

Step 2. Call Poison Control. In the United States, dial 1-800-222-1222. Have the pill bottle in hand. Specialists need the dose taken, the time of ingestion, the patient's weight, age, and any other substances consumed 10.

Step 3. Do not induce vomiting unless explicitly instructed by Poison Control or a physician. Aspiration risk is high in a sedated patient.

Step 4. Go to the emergency department if more than 20 mg was ingested, if the person cannot be roused, if opioids or alcohol were co-ingested, or if the patient is elderly or has hepatic disease.

Step 5. Bring the medication bottle. Emergency physicians need exact tablet strength and lot number.

Emergency Department Management

Initial Assessment

Emergency providers should obtain a full toxicology screen given that lemborexant overdose is clinically indistinguishable from benzodiazepine or Z-drug overdose on presentation. Standard urine immunoassay does not detect lemborexant; it requires a serum DORA-specific assay that most community hospitals do not stock 11. A negative "benzo screen" does not rule out lemborexant toxicity.

The Glasgow Coma Scale should be obtained on arrival and repeated every 30 to 60 minutes. Pulse oximetry, end-tidal CO2 if available, and a 12-lead ECG (to screen for QTc prolongation from coingestants) round out the initial workup 12.

Decontamination

Activated charcoal (1 g/kg, maximum 50 g) may reduce absorption if administered within 1 to 2 hours of ingestion and the patient has a protected airway 13. Gastric lavage is rarely indicated and reserved for massive ingestions within 60 minutes with secured airway.

Whole-bowel irrigation is not supported by evidence for lemborexant specifically. Given the drug's rapid absorption (Tmax 1 to 3 hours), benefit beyond the first hour is limited 5.

Flumazenil: Why It Does Not Work

Flumazenil reverses benzodiazepine sedation by competitively displacing the drug from the GABA-A receptor complex. Lemborexant's mechanism has nothing to do with GABA-A. Its sedation is entirely orexin-pathway mediated 14. Giving flumazenil to a lemborexant-overdosed patient wastes time, exposes the patient to seizure risk if benzodiazepine dependence is present, and provides no benefit 15.

Respiratory Support

Lemborexant alone rarely causes severe respiratory depression. The risk rises sharply when combined with opioids, alcohol, gabapentinoids, or muscle relaxants. If oxygen saturation drops below 92% or respiratory rate falls below 10, supplemental oxygen and potentially bag-valve-mask ventilation are indicated. Intubation is reserved for patients who cannot protect their airway 12.

If opioids were co-ingested and respiratory depression is profound, naloxone (0.4 to 2 mg IV/IM/IN, repeat every 2 to 3 minutes as needed) addresses the opioid component. It will not reverse the orexin-mediated sedation from lemborexant 16.

Enhanced Elimination

Hemodialysis is not expected to meaningfully enhance lemborexant elimination. Protein binding is approximately 94%, and the volume of distribution is large 5. No published case series or pharmacokinetic modeling supports dialysis as a clearance strategy for this drug class 9.

Monitoring Duration

The American College of Medical Toxicology recommends observing sedating drug overdoses until the patient is at baseline mental status, ambulatory without assistance, and able to manage secretions 17. Given lemborexant's half-life, a minimum 24-hour observation window is appropriate for any ingestion exceeding 30 mg. Patients who ingested 20 mg or less without coingestants and who are neurologically intact at 6 hours may be candidates for discharge with monitoring instructions and next-day follow-up.

Distinguishing Accidental Excess Dose From Intentional Overdose

A patient who accidentally takes two tablets instead of one (10 to 20 mg total) presents very differently from someone who ingests an entire bottle. The clinical approach diverges accordingly.

Accidental Double Dose (10 to 20 mg)

Call Poison Control. Most healthy adults without coingestants will experience prolonged somnolence but do not require emergency department evaluation. Avoid driving or operating machinery for a full 24 hours after the accidental dose 5. Elderly patients, those on CYP3A inhibitors, and anyone with hepatic impairment should be evaluated in person regardless of dose.

Large or Unknown Ingestion

Go directly to the emergency department. Do not wait for symptoms. Large DORA ingestions in combination with alcohol or opioids carry meaningful risk of respiratory compromise 9.

Intentional Self-Harm

Any suspicion of intentional overdose requires emergency psychiatric evaluation in addition to medical management, regardless of dose severity. Clinicians should screen using a validated tool such as the Columbia Suicide Severity Rating Scale 18. Disposition to a secure inpatient setting should be considered once the patient is medically stable.

Special Populations With Elevated Risk

Pediatric Exposure

Lemborexant is not approved in patients under 18. Accidental pediatric ingestion of a single 5 mg or 10 mg tablet warrants immediate Poison Control contact and likely ED evaluation, because weight-based plasma concentrations in a child will far exceed adult therapeutic levels 10.

Older Adults

SUNRISE-2 demonstrated that patients 65 and older had a somnolence incidence of 17% at 5 mg and 22% at 10 mg, versus roughly 10 to 14% in younger adults 4. An accidental double dose in an 80-year-old carries substantially greater fall and aspiration risk than the same dose in a 40-year-old.

Pregnancy

Lemborexant has no established safety data in human pregnancy. Orexin signaling appears in placental tissue and fetal brain development 19. Any overdose in a pregnant patient requires obstetric consultation alongside standard toxicology management.

Hepatic Impairment

Patients with Child-Pugh B (moderate) hepatic impairment are restricted to 5 mg maximum by the FDA label 5. Lemborexant is contraindicated in Child-Pugh C (severe) disease. An overdose in either group may require extended monitoring beyond 48 hours due to significantly reduced clearance.

Drug Interactions That Convert Therapeutic Doses Into Toxic Ones

A prescribing physician described the interaction risk plainly in a 2020 clinical pharmacology review: "CYP3A4 inhibitors increase lemborexant AUC in a magnitude that can transform a 5 mg dose into the pharmacokinetic equivalent of 20 mg or more, effectively creating a drug-induced overdose state without any patient error" 6.

The most clinically significant interactions include:

| Interacting Agent | Interaction Type | Clinical Result | |---|---|---| | Ketoconazole (strong CYP3A4 inhibitor) | Increased lemborexant AUC ~4-fold | Avoid combination entirely | | Clarithromycin | Strong CYP3A4 inhibition | Avoid combination entirely | | Diltiazem (moderate CYP3A4 inhibitor) | Increased AUC ~2-fold | Reduce lemborexant to 5 mg max | | Rifampin (strong CYP3A4 inducer) | Decreased AUC ~80% | Reduced efficacy; avoid | | Alcohol | Additive CNS depression | Contraindicated on same night | | Opioids | Additive respiratory depression | Use extreme caution; may need lower dose |

Sources: FDA prescribing information 5, Kato et al. 2020 6.

How Lemborexant Differs From Benzodiazepines and Z-Drugs in Overdose

Understanding the mechanism difference matters clinically. Benzodiazepines and Z-drugs (zolpidem, eszopiclone) enhance GABA-A receptor chloride conductance; in overdose, this produces respiratory depression that is potentially fatal and reversible with flumazenil 20.

Lemborexant works by competitive antagonism of OX1R and OX2R. It does not touch GABA-A. Respiratory drive circuits are not directly inhibited by orexin blockade alone 14. This mechanistic difference suggests that isolated lemborexant overdose (without coingestants) carries a lower respiratory fatality risk than equivalent benzodiazepine overdose, though peer-reviewed mortality data specific to lemborexant overdose remain limited to case reports as of mid-2025.

The SUNRISE-1 trial (N=1,006, JAMA Netw Open 2019) reported no respiratory-related serious adverse events at the 5 mg and 10 mg doses over 30 days 1. However, therapeutic-dose trial data cannot be extrapolated directly to supratherapeutic ingestions, and co-ingestion scenarios were excluded from both SUNRISE trials.

A 2019 comparative safety meta-analysis found that DORAs as a class were associated with significantly lower rates of next-day respiratory depression versus benzodiazepine receptor agonists, with an odds ratio of 0.31 (95% CI 0.14 to 0.69, P<0.01) for clinically significant respiratory events 21.

Post-Overdose Prescribing Considerations

After an overdose, the prescribing clinician must reassess whether lemborexant is still appropriate. Key questions include:

• Was the overdose accidental (confusion, polypharmacy) or intentional?
• Are there modifiable risk factors such as CYP3A4 inhibitor co-prescriptions?
• Is the current dose appropriate for the patient's hepatic function and age?

The Sleep Research Society's 2023 position statement on sedative-hypnotic safety recommends that prescribers use the lowest effective dose, conduct annual reassessment of continued need, and document the rationale for doses above 5 mg in patients aged 65 or older 22.

If accidental double-dosing occurred due to pill confusion, a weekly pill organizer and caregiver oversight may prevent recurrence. If intentional, the FDA's prescribing information recommends prescribing the smallest feasible quantity consistent with good patient management 5.